Previous 10 | Next 10 |
Agenus ( AGEN ) is one of the most exciting biotechnology companies available at a reasonable price today. After slumping to a 52-week low of $1.95 per share back in December 2018, news of a deal with Gilead ( GILD ) to license multiple potential cancer therapies pushed the stock back up in Ja...
Agenus (NASDAQ: AGEN ) resumed with Buy rating and $6 (36% upside) price target at B. Riley FBR. Shares up 1% premarket. More news on: Agenus Inc., Cabaletta Bio, Inc., Geron Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 131 weeks of public selections as part of this ongoing live forward-testing. In...
LEXINGTON, Mass., Nov. 12, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1 and cancer vaccines, announced that it will host a...
November 12, 2019 Palm Beach, FL –November 12, 2019 – Doctors are working to learn more about brain tumors, ways to prevent them, how to best treat them, and how to provide the best care to people diagnosed with a brain tumor. According to recent articles and...
LEXINGTON, Mass. , Nov. 11, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1 and cancer vaccines, announced today that it received $10M upfront for a License Agreement with Uro...
3 Penny Stocks to Watch in November When it comes to penny stocks , the single biggest reason why these stocks are attractive is the fact that an investor stands to make handsome profits from a relatively small investment. While that is true, it’s also important to keep in mind that a...
The following slide deck was published by Agenus Inc. in conjunction with their 2019 Q3 earnings Read more ...
Agenus Inc. (AGEN) Q3 2019 Results Conference Call November 04, 2019 08:30 AM ET Company Participants Dr. Jennifer Buell - COO Dr. Garo Armen - Chairman and CEO Anna Wijatyk - Head, Clinical Development and Operations Christine Klaskin - VP, Finance Conference Call Participa...
Agenus (NASDAQ: AGEN ): Q3 GAAP EPS of -$0.33 beats by $0.05 . Revenue of $19.94M (+55.8% Y/Y) beats by $4.34M . Press Release More news on: Agenus Inc., Earnings news and commentary, Healthcare stocks news,
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...